Search results for "302"

showing 10 items of 27399 documents

Study of the Strengths and Weaknesses of Nursing Work Environments in Primary Care in Spain

2021

Background: Nursing work environments are defined as the characteristics of the workplace that promote or hinder the provision of professional care by nurses. Positive work environments lead to better health outcomes. Our study aims to identify the strengths and weaknesses of primary health care settings in Spain. Methods: Cross-sectional study carried out from 2018 to 2019. We used the Practice Environment Scale of the Nursing Work Index and the TOP10 Questionnaire of Assessment of Environments in Primary Health Care for data collection. The associations between sociodemographic and professional variables were analyzed. Results: In total, 702 primary care nurses participated in the study. …

s roleHealth Toxicology and MutagenesisPsychological interventionlcsh:MedicinePrimary careNursingNursing Staff HospitalArticleprimary care03 medical and health sciences0302 clinical medicinenursingquality of health careNursingNurse’s roleHumansNurse Administrators030212 general & internal medicineHuman resourcesWorkplaceData collectionPrimary Health Care030504 nursingbusiness.industrylcsh:Rnurse’s rolePublic Health Environmental and Occupational HealthPrimary careWork environmentnurse&#8217workplaceCross-Sectional StudiesWork (electrical)SpainScale (social sciences)Quality of health careEnfermería0305 other medical sciencebusinessPsychologyStrengths and weaknesses
researchProduct

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea

2019

Background: Thyroid cancer has become the most common cancer in Korea. Generally, thyroid cancer patients have a good prognosis; however, 15–20% of patients experience recurrence or distant metastasis or are refractory to standard treatment. We assessed the safety of sorafenib and lenvatinib in patients with advanced or metastatic radioactive iodine-refractory differentiated thyroid cancers (DTC) consecutively treated at a tertiary center in South Korea.Methods: We retrospectively reviewed the charts of all consecutive patients with DTC treated during ≥6 months with lenvatinib (February 2016–April 2018) and sorafenib (January 2014–April 2018) at Gangnam Severance Hospital. Patients were tre…

safety0301 basic medicineSorafenibmedicine.medical_specialtyEndocrinology Diabetes and Metabolismdifferentiated thyroid cancerrefractory thyroid cancer030209 endocrinology & metabolismlenvatiniblcsh:Diseases of the endocrine glands. Clinical endocrinologyGastroenterologyPapillary thyroid cancer03 medical and health scienceschemistry.chemical_compoundEndocrinology0302 clinical medicineInternal medicinetyrosine kinase inhibitorsmedicineAdverse effectFollicular thyroid cancerThyroid cancerOriginal Researchlcsh:RC648-665business.industryStandard treatmentCancermedicine.disease030104 developmental biologychemistryadverse effectschart reviewsorafenibbusinessLenvatinibmedicine.drugFrontiers in Endocrinology
researchProduct

Online interventions to prevent mental health problems implemented in school settings: the perspectives from key stakeholders in Austria and Spain

2021

Abstract Background Schools are key settings for delivering mental illness prevention in adolescents. Data on stakeholders’ attitudes and factors relevant for the implementation of Internet-based prevention programmes are scarce. Methods Stakeholders in the school setting from Austria and Spain were consulted. Potential facilitators (e.g. teachers and school psychologists) completed an online questionnaire (N=50), policy makers (e.g. representatives of the ministry of education and health professional associations) participated in semi-structured interviews (N=9) and pupils (N=29, 14–19 years) participated in focus groups. Thematic analysis was used to identify experiences with, attitudes a…

safetyAdolescentpsychologistsPsychological interventionComputer-assisted web interviewingpupilhealth personnelprivacy03 medical and health sciences0302 clinical medicinepreventionHumansAcademicSubjects/MED00860AcademicSubjects/SOC01210030212 general & internal medicineadolescentsCurriculumschool (environment)School Health ServicesMedical educationInternetSchoolsteachersPart II: ICare Stakeholder SurveySchool psychologyPublic Health Environmental and Occupational HealthStakeholderFocus groupMental healthprevention programInternet-based intervention030227 psychiatrymental disordersMental HealthSpainattitudeAustriaThematic analysisPsychologyAcademicSubjects/SOC02610Internet-Based Interventionmental health
researchProduct

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in De…

2020

Background: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. Objective: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. Methods: The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. Results: O…

safetyAdultMalemedicine.medical_specialtyTime Factorsbiologic agentsprospective cohortlong-term follow-upDermatologyimmunosuppressive agentsanti-inflammatory agentsCohort Studies030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinePsoriasisUstekinumabmedicineAdalimumabHumansPsoriasisRegistriesAdverse effectProspective cohort studyAgedbusiness.industryregistriespsoriasis/drug therapyanti-TNFMiddle Agedmedicine.diseaseInfliximabBiological TherapySpain030220 oncology & carcinogenesispharmacovigilanceadverse effectsSecukinumabFemaleApremilastbusinessmedicine.drugJournal of the American Academy of Dermatology
researchProduct

Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor

2020

Introduction: The discovery and the clinical availability of novel cyclin-dependent kinases 4 and 6 inhibitors have profoundly changed the therapeutic scenario of metastatic hormone receptor-positive breast carcinoma. Among these inhibitors, abemaciclib can induce potent and sustained cell cycle arrest and immune system stimulation. Areas covered: This review summarizes the safety profile and clinical efficacy data on abemaciclib alone or in combination with aromatase inhibitors or fulvestrant in metastatic hormone receptor-positive breast carcinoma. The management of patients treated with abemaciclib is the object of this paper. Expert opinion: As shown in phase 2 and 3 clinical trials on …

safetyAminopyridinesBreast Neoplasms030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundabemaciclib breast cancer metastases hormonal receptors safetybreast cancer0302 clinical medicineBreast cancerCyclin-dependent kinaseAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)metastasesskin and connective tissue diseasesFulvestrantProtein Kinase InhibitorsAbemaciclibbiologyAromatase Inhibitorsbusiness.industryKinasehormonal receptorsCyclin-Dependent Kinase 4Cell Cycle CheckpointsCyclin-Dependent Kinase 6General Medicinemedicine.diseaseAbemaciclibchemistry030220 oncology & carcinogenesisQuality of LifeCancer researchbiology.proteinBenzimidazolesFemalesense organsbusinessHormone
researchProduct

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

2016

Purpose The PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed the safety, immunogenicity and clinical activity of the PRAME immunotherapeutic (recombinant PRAME protein (recPRAME) with the AS15 immunostimulant) in patients with advanced melanoma. Here, we report the phase I dose-escalation study segment. Patients and methods Patients with stage IV PRAME-positive melanoma were enrolled to 3 consecutive cohorts to receive up to 24 intramuscular injections of the PRAME immunotherapeutic. The RecPRAME dose was 20, 100 or 500 µg in cohorts 1, 2 and 3, respectively, with a fixed dose of AS15. Advers…

safetyCancer Researchmedicine.drug_classmedicine.medical_treatmentMedizinPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerimmunogenicityImmunostimulant03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerCancer immunotherapymedicine1506030304 developmental biologyOriginal ResearchPRAME antigen0303 health sciencesPRAMEcancer immunotherapybusiness.industryMelanomaImmunogenicityCancermedicine.disease3. Good healthOncology030220 oncology & carcinogenesisImmunologyChillsmedicine.symptombusinessmetastatic melanoma
researchProduct

Polyphenols and Pharmacological Screening of a Monarda fistulosa L. dry Extract Based on a Hydrodistilled Residue By-Product

2021

This study aimed to determine the composition and content of polyphenols in the dry extract obtained from the hydrodistilled residue by-product of the wild bergamot (Monarda fistulosa L., Lamiaceae Martinov family) herb (MFDE) and to evaluate its safety and pharmacological properties. The total phenolic content (TPC) in the MFDE was 120.64 mg GAE/g. The high-performance liquid chromatography (HPLC) analysis showed the presence of a plethora of phenolic compounds, including hydroxycinnamic acids and flavone derivatives in the MFDE, with rosmarinic acid and luteolin-7-O-glucoside being the main components. With an IC50 value of 0.285 mg/mL, it was found to be a strong DPPH radical scavenger. …

safetyDPPHRM1-950phenolic compoundsMonarda fistulosa01 natural sciencesHigh-performance liquid chromatographywild bergamot03 medical and health scienceschemistry.chemical_compound0302 clinical medicineantiradical activityPharmacology (medical)anti-inflammatory activityanalgesic activityOriginal ResearchPharmacologyResidue (complex analysis)biologyTraditional medicine010405 organic chemistryRosmarinic acidbiology.organism_classificationAcute toxicity0104 chemical scienceschemistryherbPolyphenol030220 oncology & carcinogenesispostdistillation wasteLamiaceaeTherapeutics. PharmacologyFrontiers in Pharmacology
researchProduct

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

2020

Funding: Transgène; International audience; Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity and resolution of infection. TG1050 is an adenovirus 5-based vaccine that expresses HBV polymerase and domains of core and surface antigen and has shown immunogenicity and antiviral effects in mice. We performed a phase 1 clinical trial to assess safety and explore immunogenicity and early efficacy of TG1050 in CHB patients. This randomized, double blind, placebo-controlled study included two sequential phases: one single dose cohort (SD, n = 12) and one …

safetyHBsAg030231 tropical medicineImmunologyPlacebo-controlled studyPhases of clinical researchSciences du Vivant [q-bio]/Médecine humaine et pathologieimmunogenicityPlaceboAntiviral AgentsAdenoviridae03 medical and health sciencesMice0302 clinical medicineHepatitis B ChronicImmunogenicity VaccinevaccineImmunology and AllergyMedicineAnimalsHumans030212 general & internal medicineAdverse effectPharmacologyVaccinesHepatitis B Surface Antigens[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryELISPOTImmunogenicitychronicityimmuno-therapyHepatitis Bmedicine.diseaseHepatitis B3. Good healthImmunologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyResearch Paper
researchProduct

Tenapanor for the treatment of irritable bowel syndrome with constipation.

2020

Introduction: Irritable bowel syndrome with constipation is associated with higher rates of functional impairment, as compared to other subtypes of the syndrome. Conventional laxative-based pharmacologic therapy of IBS-C, which is mostly symptom-based, is often unsatisfactory. Tenapanor represents a first-in-class orally available inhibitor of NHE3, which is minimally absorbed in the GI tract, what constitutes a significant therapeutic benefit, as it may act on the drug target. Areas covered: Aim of this article is to sum up the evidences about pharmacodynamics and pharmacokinetics of tenapanor, focusing on animal models and in vitro studies, but also discuss clinical trials on tenapanor's …

safetymedicine.medical_specialtyFunctional impairmentConstipationmedicine.medical_treatmentefficacyLaxative030226 pharmacology & pharmacyGastroenterologyIrritable Bowel Syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGastrointestinal AgentsInternal medicinemedicineAnimalsHumansPharmacology (medical)Pharmacologic therapyDrug InteractionsGeneral Pharmacology Toxicology and PharmaceuticsTenapanorIrritable bowel syndromeSulfonamidesbusiness.industrySodium-Hydrogen Exchanger 3General Medicinemedicine.diseaseIsoquinolinestenapanor.chemistry030220 oncology & carcinogenesismedicine.symptombusinessConstipationExpert review of clinical pharmacology
researchProduct

Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with …

2019

ObjectiveOur aim was to summarize the efficacy and safety of atomoxetine, amphetamines, and methylphenidate in schizophrenia.MethodsWe undertook a systematic review, searching PubMed/Scopus/Clinicaltrials.gov for double-blind, randomized, placebo-controlled studies of psychostimulants or atomoxetine in schizophrenia published up to 1 January 2017. A meta-analysis of outcomes reported in two or more studies is presented.ResultsWe included 22 studies investigating therapeutic effects of stimulants (k=14) or measuring symptomatic worsening/relapse prediction after stimulant challenge (k=6). Six studies of these two groups plus one additional study investigated biological effects of psychostimu…

safetymedicine.medical_specialtyPsychosismedicine.medical_treatmentefficacyamphetamineSchizoaffective disorderAtomoxetine Hydrochloridemeta-analysi03 medical and health sciencesExecutive Function0302 clinical medicinesystematic reviewInternal medicinemedicineHumansAttentionAmphetamineProblem Solvingbusiness.industryMethylphenidateAtomoxetineAmphetaminesrelapse predictorstimulantmedicine.disease030227 psychiatryStimulantPsychiatry and Mental healthMemory Short-Termamphetamine atomoxetine efficacy meta-analysis methylphenidate relapse predictor safety schizophrenia stimulants systematicn reviewPsychotic DisordersSchizophreniaMeta-analysisMethylphenidateSchizophreniaNeurology (clinical)businessatomoxetine030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct